If multiple autism prevalence studies met this criterion for a given country, a weighted average based on study population size was calculated.
Similarly, for states with multiple studies in a time period, a summary prevalence was calculated using a weighted average based on study population size.
For countries with multiple studies in a time period, a summary prevalence was calculated using a weighted average based on study population size (Additional file 3).
Studies were weighted based on study sample sizes.
Guidance is provided on interval construction method selection based on study design, sample size, and normality of the data.
For judgement, the strength of evidence for a risk association, the level of evidence, and the number of studies were considered, the quality of the studies and their estimated relevance based on study design and size.
As there was heterogeneity existing among included studies, we also conducted subgroup analyses based on study region, sample size, cut-off value of NLR, therapeutic intervention, type of RCC and NOS score.
In cases of discordant published data, the evidence is weighted based on study design and size, with larger studies and those that do not raise concerns about study methods (such as use of co-medications and genotype groupings that might skew the expected outcomes) carrying more weight.
Thirteen studies were identified and included in the review and analyzed based on study design, population, sample size, measures of balance, main outcome measures, and evaluation of validity and reliability.
One researcher (EM) identified relevant trials based on study ID, indication, sample size, study duration, and dose groups.
